Table 3.
Clinicopathologic factors associated with mRECIST responder and nonresponder groups
| Clinicopathologic factors | Overall | Responder (n=50) | Nonresponder (n=76) | P-value |
|---|---|---|---|---|
| Sex | ||||
| Male | 90 | 34 | 56 | 0.548 |
| Female | 36 | 16 | 20 | |
| Age (years) | ||||
| ≥55 | 87 | 39 | 48 | 0.115 |
| <55 | 39 | 11 | 28 | |
| HBsAg | ||||
| Positive | 100 | 38 | 62 | 0.503 |
| Negative | 26 | 12 | 14 | |
| Liver cirrhosis | ||||
| Presence | 98 | 35 | 63 | 0.125 |
| Absence | 28 | 15 | 13 | |
| Child–Pugh classification | ||||
| Class A | 97 | 35 | 62 | 0.533 |
| Class B | 29 | 15 | 14 | |
| Tumor size (cm) | ||||
| ≤5 | 67 | 41 | 18 | <0.001 |
| >5 | 59 | 9 | 58 | |
| AFP (ng/mL) | ||||
| ≤400 | 60 | 29 | 31 | 0.070 |
| >400 | 66 | 21 | 45 | |
| Number of tumors | ||||
| 1 | 43 | 13 | 30 | 0.129 |
| ≥2 | 83 | 37 | 46 | |
| Vascular invasion | ||||
| Presence | 37 | 10 | 27 | 0.073 |
| Absence | 89 | 40 | 49 | |
| BCLC stage | ||||
| A | 33 | 20 | 13 | 0.006 |
| B | 58 | 22 | 36 | |
| C | 35 | 8 | 27 |
Abbreviations: AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; HBsAg, hepatitis B surface antigen; mRECIST, modified response evaluation criteria.